NXTC Key Statistics, Chart & Performance
The current stock price of NXTC is 12.73 USD. In the past month the price increased by 32.19%. In the past year, price decreased by -6.94%.
NXTC Latest News, Press Relases and Analysis
NXTC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.2 | 404.22B | ||
| AMGN | AMGEN INC | 15.55 | 183.17B | ||
| GILD | GILEAD SCIENCES INC | 14.97 | 152.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.35 | 116.04B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.06 | 75.97B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 912.43 | 61.48B | ||
| INSM | INSMED INC | N/A | 43.73B | ||
| NTRA | NATERA INC | N/A | 33.41B | ||
| BIIB | BIOGEN INC | 10.87 | 26.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.34 | 20.85B | ||
| INCY | INCYTE CORP | 15.65 | 19.72B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.19B |
Related stock screener links
About NXTC
Company Profile
NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. The company is headquartered in Beltsville, Maryland and currently employs 43 full-time employees. The company went IPO on 2019-05-09. The company focuses on advancing therapies that leverage its core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. Its product candidate, LNCB74, is designed as a B7-H4 targeted ADC to kill tumors. Its clinical oncology programs include NC410 and NC525. NC410 is a fusion protein of LAIR-2, a naturally occurring soluble version of, and decoy protein for, LAIR-1 that is designed to block immune suppression mediated by LAIR-1. NC525 is a novel LAIR-1 antibody that selectively targets Acute Myeloid Leukemia (AML), blast cells and leukemic stem cells.
Company Info
NEXTCURE INC
9000 Virginia Manor Rd Ste 200
Beltsville MARYLAND 20705 US
CEO: Michael Richman
Employees: 43
Phone: 12403994900
NEXTCURE INC / NXTC FAQ
What does NEXTCURE INC do?
NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. The company is headquartered in Beltsville, Maryland and currently employs 43 full-time employees. The company went IPO on 2019-05-09. The company focuses on advancing therapies that leverage its core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. Its product candidate, LNCB74, is designed as a B7-H4 targeted ADC to kill tumors. Its clinical oncology programs include NC410 and NC525. NC410 is a fusion protein of LAIR-2, a naturally occurring soluble version of, and decoy protein for, LAIR-1 that is designed to block immune suppression mediated by LAIR-1. NC525 is a novel LAIR-1 antibody that selectively targets Acute Myeloid Leukemia (AML), blast cells and leukemic stem cells.
What is the current price of NXTC stock?
The current stock price of NXTC is 12.73 USD. The price increased by 5.77% in the last trading session.
Does NEXTCURE INC pay dividends?
NXTC does not pay a dividend.
What is the ChartMill rating of NEXTCURE INC stock?
NXTC has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the analyst forecast for NXTC stock?
9 analysts have analysed NXTC and the average price target is 18.02 USD. This implies a price increase of 41.56% is expected in the next year compared to the current price of 12.73.
How many employees does NEXTCURE INC have?
NEXTCURE INC (NXTC) currently has 43 employees.
NXTC Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to NXTC. When comparing the yearly performance of all stocks, NXTC is one of the better performing stocks in the market, outperforming 95.9% of all stocks.
NXTC Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NXTC. NXTC scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
NXTC Financial Highlights
Over the last trailing twelve months NXTC reported a non-GAAP Earnings per Share(EPS) of -24.11. The EPS decreased by -90.59% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -146.44% | ||
| ROE | -245.33% | ||
| Debt/Equity | 0 |
NXTC Forecast & Estimates
9 analysts have analysed NXTC and the average price target is 18.02 USD. This implies a price increase of 41.56% is expected in the next year compared to the current price of 12.73.